Long-term survival after liver transplantation in 4,000 consecutive patients at a single center.

PubWeight™: 2.91‹?› | Rank: Top 1%

🔗 View Article (PMC 1421181)

Published in Ann Surg on October 01, 2000

Authors

A Jain1, J Reyes, R Kashyap, S F Dodson, A J Demetris, K Ruppert, K Abu-Elmagd, W Marsh, J Madariaga, G Mazariegos, D Geller, C A Bonham, T Gayowski, T Cacciarelli, P Fontes, T E Starzl, J J Fung

Author Affiliations

1: Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Associated clinical trials:

Removable Intraductal Stenting in Duct-to-duct Biliary Reconstruction in Liver Transplantation (BILIDRAINT) | NCT02356939

Articles citing this

The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med (2011) 3.80

Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant (2010) 1.93

Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation. Liver Transpl (2013) 1.88

Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg (2005) 1.73

Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl (2005) 1.61

Recipient survival and graft survival are not diminished by simultaneous liver-kidney transplantation: an analysis of the united network for organ sharing database. Liver Transpl (2012) 1.54

Analysis of adult 20-year survivors after liver transplantation. Hepatol Int (2014) 1.45

Extensive multifocal branch duct IPMN of the pancreas after liver transplantation: is surgery justified? Eur J Med Res (2015) 1.40

Low-volume deceased donor liver transplantation alongside a strong living donor liver transplantation service. World J Surg (2014) 1.40

Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg (2002) 1.16

Biliary strictures after liver transplantation. Gut Liver (2011) 1.09

Defining readmission risk factors for liver transplantation recipients. Gastroenterol Hepatol (N Y) (2011) 1.01

Hepatic artery embolization for treatment of patients with hereditary hemorrhagic telangiectasia and symptomatic hepatic vascular malformations. Eur Radiol (2004) 1.01

Subnormothermic machine perfusion for ex vivo preservation and recovery of the human liver for transplantation. Am J Transplant (2014) 0.97

Pediatric liver transplantation. A single center experience spanning 20 years. Transplantation (2002) 0.95

Liver transplantation. Gut Liver (2009) 0.93

Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl (2001) 0.93

Sexual dimorphism in reduced-size liver ischemia and reperfusion injury in mice: role of endothelial cell nitric oxide synthase. Proc Natl Acad Sci U S A (2003) 0.92

Life expectancy of adult liver allograft recipients in the UK. Gut (2006) 0.91

Auxiliary partial orthotopic versus standard orthotopic whole liver transplantation for acute liver failure: a reappraisal from a single center by a case-control study. Ann Surg (2001) 0.89

Evolution and management of de novo neoplasm post-liver transplantation: a 20-year experience from a single European centre. Hepatol Int (2010) 0.86

Liver transplantation in the Nordic countries - An intention to treat and post-transplant analysis from The Nordic Liver Transplant Registry 1982-2013. Scand J Gastroenterol (2015) 0.86

Microbubble ultrasound contrast in the assessment of hepatic artery patency following liver transplantation: role in reducing frequency of hepatic artery arteriography. Eur Radiol (2003) 0.84

Pediatric liver transplantation in 808 consecutive children: 20-years experience from a single center. Transplant Proc (2002) 0.84

Acute graft versus host disease after orthotopic liver transplantation. J Hematol Oncol (2012) 0.83

Causes of death after liver transplantation in 4000 consecutive patients: 2 to 19 year follow-up. Transplant Proc (2001) 0.82

Multidrug donor preconditioning prevents cold liver preservation and reperfusion injury. Langenbecks Arch Surg (2010) 0.81

Causes of retransplantation after primary liver transplantation in 4000 consecutive patients: 2 to 19 years follow-up. Transplant Proc (2001) 0.81

Estrogen Sulfotransferase Is an Oxidative Stress-responsive Gene That Gender-specifically Affects Liver Ischemia/Reperfusion Injury. J Biol Chem (2015) 0.81

Liver retransplantation in adults: a single-centre, 25-year experience. HPB (Oxford) (2010) 0.80

Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. Value Health (2016) 0.80

Endoscopic Management of Anastomotic Strictures after Liver Transplantation. Clin Endosc (2016) 0.79

The effect of estrogen on hepatic microcirculation after ischemia/reperfusion. Int J Colorectal Dis (2007) 0.79

Historical perspective of living donor liver transplantation. World J Gastroenterol (2008) 0.79

Impact of early reoperation following living-donor liver transplantation on graft survival. PLoS One (2014) 0.78

Q-FISH measurement of hepatocyte telomere lengths in donor liver and graft after pediatric living-donor liver transplantation: donor age affects telomere length sustainability. PLoS One (2014) 0.78

Gender differences in hepatic ischemic reperfusion injury in rats are associated with endothelial cell nitric oxide synthase-derived nitric oxide. World J Gastroenterol (2005) 0.78

Intent-to-treat analysis of liver transplant for hepatocellular carcinoma in the MELD era: impact of hepatitis C and advanced status. Dig Dis Sci (2014) 0.78

Beyond the Pediatric end-stage liver disease system: solutions for infants with biliary atresia requiring liver transplant. World J Gastroenterol (2014) 0.78

Spontaneous Bacterial Peritonitis. Curr Treat Options Gastroenterol (2002) 0.78

Liver transplantation(). J Ultrasound (2007) 0.77

Celsior versus University of Wisconsin preserving solutions for liver transplantation: postreperfusion syndrome and outcome of a 5-year prospective randomized controlled study. World J Surg (2011) 0.77

Kidney function and mortality post-liver transplant in the Model for End-Stage Liver Disease era. Int J Nephrol Renovasc Dis (2011) 0.77

Toll-like receptors in secondary obstructive cholangiopathy. Gastroenterol Res Pract (2011) 0.75

Immunological basis for treatment of graft versus host disease after liver transplant. Expert Rev Clin Immunol (2016) 0.75

Evaluating the Cost-Effectiveness of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus in Liver Transplant Patients Based on Data from Routine Clinical Practice. Drugs Real World Outcomes (2016) 0.75

The benefit of sirolimus maintenance immunosuppression and rabbit antithymocyte globulin induction in liver transplant recipients that develop acute kidney injury in the early postoperative period. J Transplant (2015) 0.75

Evaluating twenty-years of follow-up after orthotopic liver transplantation, best practice for donor-recipient matching: What can we learn from the past era? World J Transplant (2016) 0.75

Increasing Organ Donor Registration in a Primary Care Clinic. BMJ Qual Improv Rep (2017) 0.75

When and Where to Transfer for Bayes Net Parameter Learning. Expert Syst Appl (2016) 0.75

Outcomes of liver transplantation in patients with hepatorenal syndrome. World J Hepatol (2016) 0.75

Pre-Transplant Depression Is Associated with Length of Hospitalization, Discharge Disposition, and Survival after Liver Transplantation. PLoS One (2016) 0.75

Immunizations in solid organ and hematopoeitic stem cell transplant patients: A comprehensive review. Hum Vaccin Immunother (2015) 0.75

Current strategies for immunosuppression following liver transplantation. Langenbecks Arch Surg (2014) 0.75

Russell Strong and the history of reduced-size liver transplantation. World J Surg (2009) 0.75

Retransplantation in Late Hepatic Artery Thrombosis: Graft Access and Transplant Outcome. Transplant Direct (2017) 0.75

Role of natural killer cells in liver transplantation treatment of liver cancer. Exp Ther Med (2017) 0.75

Orchiectomy or testosterone receptor blockade reduces intestinal mucosal damage caused by ischemia-reperfusion insult. Pediatr Surg Int (2007) 0.75

Influence of ultrasound contrast agents on spectral Doppler analysis in recipients of liver transplantation. Clin Mol Hepatol (2017) 0.75

Risk Factors and Outcomes of De novo Cancers (Excluding Nonmelanoma Skin Cancer) after Liver Transplantation for Primary Sclerosing Cholangitis. Transplantation (2017) 0.75

Articles cited by this

Evolution of liver transplantation. Hepatology (1982) 19.54

Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet (1979) 12.29

Reconstructive problems in canine liver homotransplantation with special reference to the postoperative role of hepatic venous flow. Surg Gynecol Obstet (1960) 11.73

HOMOTRANSPLANTATION OF THE LIVER IN HUMANS. Surg Gynecol Obstet (1963) 10.22

Experimental whole-organ transplantation of the liver and of the spleen. Ann Surg (1960) 9.58

Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med (1994) 4.22

Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 4.10

Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet (1994) 3.72

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

Long-term survival after retransplantation of the liver. Ann Surg (1997) 1.91

Is the pathologic TNM staging system for patients with hepatoma predictive of outcome? Cancer (2000) 1.82

The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg (1996) 1.71

Long-term results of pediatric liver transplantation: an analysis of 569 transplants. Ann Surg (1998) 1.59

Influence of donor age on graft survival after liver transplantation--United Network for Organ Sharing Registry. Liver Transpl Surg (1995) 1.51

Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann Surg (1994) 1.33

Effect of donor age and sex on the outcome of liver transplantation. Hepatology (1995) 1.31

Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation (1998) 1.28

Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology (1997) 1.21

Early death or retransplantation in adults after orthotopic liver transplantation. Can outcome be predicted? Transplantation (1994) 1.18

Liver transplantation in the United States from 1987-1998: updated results from the Pitt-UNOS Liver Transplant Registry. Clin Transpl (1998) 1.17

Age and liver transplantation: a report of the Liver Transplantation Database. Transplantation (1998) 1.13

Ten years of liver transplantation: an evolving understanding of late graft loss. Transplantation (1997) 1.10

Liver transplantation under cyclosporine: a decade of experience. Transplant Proc (1991) 1.07

Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. Transplantation (2000) 1.06

An analysis of late deaths after liver transplantation. Transplantation (1996) 1.06

What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg (1999) 1.02

Retransplantation for late liver graft failure: predictors of mortality. Liver Transpl (2000) 0.92

Disease recurrence following liver transplantation. Am J Surg Pathol (1990) 0.91

Hepatitis viruses and liver transplantation. J Gastroenterol Hepatol (1997) 0.89

The Cambridge and King's College Hospital experience of liver transplantation, 1968-1983. Hepatology (1984) 0.86

Early detection of de novo hepatitis C infection in patients after liver transplantation by reverse transcriptase polymerase chain reaction. Surgery (1993) 0.84

Fifteen-year experience with adult and pediatric liver transplantation at the University of California, Los Angeles. Clin Transpl (1998) 0.83

Liver transplantation in Birmingham: indications, results, and changes. Clin Transpl (1996) 0.82

Successful liver transplantation after induction chemotherapy in children with inoperable, multifocal primary hepatic malignancy. Transplantation (1999) 0.82

The University of Toronto liver transplant program. Clin Transpl (1996) 0.81

Use of intrahepatic chemotherapy to treat advanced pediatric hepatic malignancies. J Pediatr Gastroenterol Nutr (2000) 0.81

Failed allografts and causes of death after orthotopic liver transplantation from 1985 to 1995: decreasing prevalence of irreversible hepatic allograft rejection. Liver Transpl Surg (1996) 0.81

Recurrence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis. Liver Transpl Surg (1995) 0.81

Recurrent disease after liver transplantation. Semin Gastrointest Dis (1998) 0.80

Articles by these authors

Evolution of liver transplantation. Hepatology (1982) 19.54

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24

A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet (1984) 10.33

The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Orthotopic liver transplantation in ninety-three patients. Surg Gynecol Obstet (1976) 8.11

The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40

The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24

Fifteen years of clinical liver transplantation. Gastroenterology (1979) 7.19

Venous bypass in clinical liver transplantation. Ann Surg (1984) 7.04

Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Orthotopic homotransplantation of the human liver. Ann Surg (1968) 6.64

Vascular homografts from cadaveric organ donors. Surg Gynecol Obstet (1979) 6.23

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74

Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70

Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54

Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc (1974) 5.53

Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery (1968) 5.44

Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39

Cyclophosphamide and whole organ transplantation in human beings. Surg Gynecol Obstet (1971) 5.24

Alternative methods of arterialization of the hepatic graft. Surg Gynecol Obstet (1984) 5.16

Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

Liver transplantation (1). N Engl J Med (1989) 4.53

Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet (1984) 4.49

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29

Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29

Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16

Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12

Malignant lymphomas in transplantation patients. Transplant Proc (1969) 4.12

Role of liver transplantation in cancer therapy. Ann Surg (1985) 4.08

Biliary complications after liver transplantation: with special reference to the biliary cast syndrome and techniques of secondary duct repair. Surgery (1977) 4.08

Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05

Baboon-to-human liver transplantation. Lancet (1993) 4.01

Extended preservation of human liver grafts with UW solution. JAMA (1989) 3.99

Canine and human liver preservation for 6 to 18 hr by cold infusion. Transplantation (1977) 3.99

Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92

Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation (1985) 3.91

The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions. Surg Gynecol Obstet (1967) 3.86

Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85

The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet (1973) 3.84

Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet (1976) 3.74

Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73

Hepatic trisegmentectomy and other liver resections. Surg Gynecol Obstet (1975) 3.66

Right trisegmentectomy for hepatic neoplasms. Surg Gynecol Obstet (1980) 3.64

Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Hepatic Retransplantation. Transplant Proc (1985) 3.62

Internal hernia: clinical and imaging findings in 17 patients with emphasis on CT criteria. Radiology (2001) 3.60

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55

Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54

Combination donor hepatectomy and nephrectomy and early functional results of allografts. Surg Gynecol Obstet (1982) 3.49

Long-term survival after renal transplantation in humans: (with special reference to histocompatibility matching, thymectomy, homograft glomerulonephritis, heterologous ALG , AND RECIPIENT MALIGNANCY). Ann Surg (1970) 3.48

Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43

Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J Exp Med (1992) 3.42

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet (1981) 3.38

The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation (1985) 3.38

Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

Delayed biliary duct obstruction after orthotopic liver transplantation. Surgery (1972) 3.26

The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24

Changes in blood coagulation. Arch Surg (1966) 3.22